Matt Miksic
Stock Analyst at Barclays
(3.58)
# 720
Out of 5,182 analysts
346
Total ratings
54.61%
Success rate
3.76%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EW Edwards Lifesciences | Maintains: Overweight | $104 → $110 | $81.60 | +34.80% | 33 | Apr 27, 2026 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $712 → $651 | $467.69 | +39.19% | 10 | Apr 23, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $100 → $96 | $58.75 | +63.40% | 22 | Apr 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Overweight | $144 → $143 | $93.76 | +52.52% | 34 | Apr 20, 2026 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $234 → $255 | $228.96 | +11.37% | 17 | Apr 15, 2026 | |
| HUMA Humacyte | Maintains: Overweight | $3.5 → $1.5 | $0.78 | +91.47% | 2 | Apr 8, 2026 | |
| MDT Medtronic | Maintains: Overweight | $118 → $120 | $82.19 | +46.00% | 26 | Apr 1, 2026 | |
| MMED MiniMed Group | Initiates: Overweight | $26 | $13.01 | +99.85% | 1 | Apr 1, 2026 | |
| COO The Cooper Companies | Maintains: Overweight | $98 → $103 | $63.35 | +62.59% | 3 | Mar 6, 2026 | |
| LIVN LivaNova | Maintains: Equal-Weight | $67 → $73 | $61.17 | +19.34% | 10 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $86 → $90 | $75.14 | +19.78% | 11 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $118 → $123 | $91.79 | +34.00% | 17 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $20 | $15.78 | +26.74% | 7 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $71 → $72 | $60.17 | +19.66% | 10 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $18.33 | +36.39% | 24 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $104 → $100 | $83.56 | +19.67% | 10 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $202 | $149.34 | +35.26% | 2 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $86 → $87 | $69.40 | +25.36% | 2 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $316 → $274 | $185.08 | +48.04% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $12 | $3.91 | +207.30% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $27 | $9.81 | +175.23% | 5 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $55 | $19.06 | +188.56% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1.5 → $31 | $7.30 | +324.66% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $322.92 | +40.28% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $14.22 | +47.68% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $5.68 | +287.32% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $76.11 | +31.39% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $176.86 | +136.35% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $15.40 | +81.82% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $11.78 | +468.76% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $10.58 | +722.31% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $2.39 | +946.03% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | - | - | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $3.37 | +167.46% | 1 | Dec 12, 2016 |
Edwards Lifesciences
Apr 27, 2026
Maintains: Overweight
Price Target: $104 → $110
Current: $81.60
Upside: +34.80%
Intuitive Surgical
Apr 23, 2026
Maintains: Overweight
Price Target: $712 → $651
Current: $467.69
Upside: +39.19%
Boston Scientific
Apr 23, 2026
Maintains: Overweight
Price Target: $100 → $96
Current: $58.75
Upside: +63.40%
Abbott Laboratories
Apr 20, 2026
Maintains: Overweight
Price Target: $144 → $143
Current: $93.76
Upside: +52.52%
Johnson & Johnson
Apr 15, 2026
Maintains: Equal-Weight
Price Target: $234 → $255
Current: $228.96
Upside: +11.37%
Humacyte
Apr 8, 2026
Maintains: Overweight
Price Target: $3.5 → $1.5
Current: $0.78
Upside: +91.47%
Medtronic
Apr 1, 2026
Maintains: Overweight
Price Target: $118 → $120
Current: $82.19
Upside: +46.00%
MiniMed Group
Apr 1, 2026
Initiates: Overweight
Price Target: $26
Current: $13.01
Upside: +99.85%
The Cooper Companies
Mar 6, 2026
Maintains: Overweight
Price Target: $98 → $103
Current: $63.35
Upside: +62.59%
LivaNova
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $67 → $73
Current: $61.17
Upside: +19.34%
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $86 → $90
Current: $75.14
Upside: +19.78%
Feb 25, 2026
Maintains: Overweight
Price Target: $118 → $123
Current: $91.79
Upside: +34.00%
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $17 → $20
Current: $15.78
Upside: +26.74%
Feb 13, 2026
Maintains: Underweight
Price Target: $71 → $72
Current: $60.17
Upside: +19.66%
Feb 13, 2026
Maintains: Overweight
Price Target: $30 → $25
Current: $18.33
Upside: +36.39%
Feb 12, 2026
Maintains: Underweight
Price Target: $104 → $100
Current: $83.56
Upside: +19.67%
Feb 11, 2026
Reinstates: Overweight
Price Target: $202
Current: $149.34
Upside: +35.26%
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $86 → $87
Current: $69.40
Upside: +25.36%
Jan 12, 2026
Downgrades: Underweight
Price Target: $316 → $274
Current: $185.08
Upside: +48.04%
Jan 9, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $3.91
Upside: +207.30%
Jan 7, 2026
Maintains: Overweight
Price Target: $23 → $27
Current: $9.81
Upside: +175.23%
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $19.06
Upside: +188.56%
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $7.30
Upside: +324.66%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $322.92
Upside: +40.28%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $14.22
Upside: +47.68%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $5.68
Upside: +287.32%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $76.11
Upside: +31.39%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $176.86
Upside: +136.35%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $15.40
Upside: +81.82%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $11.78
Upside: +468.76%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $10.58
Upside: +722.31%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $2.39
Upside: +946.03%
Oct 10, 2017
Maintains: Buy
Price Target: $26 → $24
Current: -
Upside: -
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $3.37
Upside: +167.46%